Masters of Longevity - The Pulse

Fight Aging!17 Jun 2026
AINaked Mole Rats Exhibit a Consistently Low Resting Metabolic Rate with Aging (Fight Aging!)

Naked Mole Rats Exhibit a Consistently Low Resting Metabolic Rate with Aging

Examine how a eusocial subterranean mammal maintains a low, age-stable resting metabolic rate across individual and colony contexts and environmental explanations.

Key takeaways
  • Larger species are on average longer lived and have lower metabolic rates.
  • Number of interesting outliers that exhibit very long lives relative to similarly sized mammalian species.
  • There is a great deal of complexity under the hood here.
Longevity Technology17 Jun 2026
AITelomir Pharmaceuticals’ new drug reverses insulin resistance in diabetes study (Longevity Technology)

Telomir Pharmaceuticals’ new drug reverses insulin resistance in diabetes study

Report on preclinical data for a small-molecule diabetes candidate tested in an animal model and its potential development implications.

Key takeaways
  • HOMA-IR declined from about 10–12 to roughly 3 after 14 days of treatment.
  • Compound has FDA IND clearance for a Phase 1/2 triple-negative breast cancer trial.
  • Telomir-Zn restored insulin sensitivity in a diet-induced zebrafish model dose-dependently.
Fight Aging!17 Jun 2026
AIThrombospondin-1 Secreted by Senescent Cells Impairs Bone Regeneration (Fight Aging!)

Thrombospondin-1 Secreted by Senescent Cells Impairs Bone Regeneration

Analysis of how a senescence-associated secretome factor reshapes immune interactions in aging bone and regeneration processes.

Key takeaways
  • There are likely countless mechanisms of this nature taking place in the aging body.
  • It has been shown in the past to induce blood-brain barrier dysfunction.
  • Accumulation of senescent cells with age is known to be an important aspect of degenerative aging.
Longevity Technology17 Jun 2026
AIBioAge starts mid-stage trial for oral drug targeting heart disease risk (Longevity Technology)

BioAge starts mid-stage trial for oral drug targeting heart disease risk

A clinical study testing an oral therapy to reduce cardiovascular inflammation risk. Read for trial design details and industry context.

Key takeaways
  • QUELL-CV will randomize approximately 160 adults in a 12-week dose-ranging Phase 2 trial.
  • Phase 1 study showed median hsCRP reductions of 86% at selected doses.
  • Primary endpoint is percent change in high-sensitivity C-reactive protein.